Brentuximab Vedotin Monotherapy in Relapsed/Refractory T Cell Lymphoma Setting-Real Life Data

Basit Öğe Kaydı
dc.authoridTahir Darçın / 0000-0001-5073-1790
dc.authoridIstemi Serın / 0000-0003-1855-774X
dc.authoridMehmet Can Ugur / 0000-0002-5600-3169
dc.authoridOmer Ekinci / 0000-0002-4636-3590
dc.authoridIpek Yonal-Hindilerden / 0000-0003-1353-2367
dc.authoridSeval Akpınar / 0000-0002-6961-8971
dc.authoridTuba Hacibekiroglu / 0000-0003-1814-5972
dc.authoridSinan Demircioğlu / 0000-0003-1277-5105
dc.authoridEmine Gültürk / 0000-0003-2836-6162
dc.authoridMurat Albayrak / 0000-0003-4025-741X
dc.authoridIsmet Aydogdu / 0000-0001-9350-1485
dc.authoridMehmet Sınan Dal / 0000-0002-5994-2735
dc.authoridMehmet Hilmi Doğu / 0000-0001-7237-2637
dc.authoridSinem Namdaroglu / 0000-0002-8074-7301
dc.authoridAli Doğan / 0000-0003-0207-3505
dc.authoridMeliha Nalcaci / 0000-0002-2555-5024
dc.authoridBurhan Turgut / 0000-0001-5729-0043
dc.authoridSemih Başcı / 0000-0003-4304-9245
dc.authoridFevzi Altuntas / 0000-0001-6872-3780
dc.authorscopusidMehmet Hilmi Doğu / 55212747300
dc.authorwosidMehmet Hilmi Doğu / W-2255-2017
dc.contributor.authorDarçın, Tahir
dc.contributor.authorSerın, Istemi
dc.contributor.authorUgur, Mehmet Can
dc.contributor.authorEkinci, Omer
dc.contributor.authorHindilerden, Ipek Yonal
dc.contributor.authorAkpınar, Seval
dc.contributor.authorHacibekiroglu, Tuba
dc.contributor.authorDemircioğlu, Sinan
dc.contributor.authorGültürk, Emine
dc.contributor.authorAlbayrak, Murat
dc.contributor.authorAydogdu, Ismet
dc.contributor.authorDal, Mehmet Sınan
dc.contributor.authorDoğu, Mehmet Hilmi
dc.contributor.authorNamdaroglu, Sinem
dc.contributor.authorDoğan, Ali
dc.contributor.authorNalcaci, Meliha
dc.contributor.authorTurgut, Burhan
dc.contributor.authorBaşcı, Semih
dc.contributor.authorAltuntas, Fevzi
dc.date.accessioned2025-04-18T08:19:01Z
dc.date.available2025-04-18T08:19:01Z
dc.date.issued23.07.2024
dc.departmentİstinye Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü
dc.description.abstractObjective: We present data of patients with relapsed/ refractory T cell lymphomas treated with brentuximab vedotin (BV) in real-world practice. Material and Method: This study is an observational, multi-center, retrospective study. The data of patients (n=17) treated with BV alone from January 2014 until July 2020 in thirteen centers from Turkey were collected. Results: Bv was given as salvage chemotherapy to 17 patients with median age of 53. Nine (52.9%) patients had diagnosis of peripheral T cell lymphoma, not otherwise specified; 8 (47.1%) patients had anaplastic large T cell lymphoma. The median follow-up of the cohort was 20 months. Nine (52.9%) patients had complete response, 5 (29.5%) had partial response, 3 (17.6%) had progressive disease. The safety results aligned with the established profile of BV, included 2 pneumonia and 1 thrombocytopenia with grade 4. The median progression free survival of the cohort was 10 months. BV cycle and response to BV therapy were found to have an effect on the univariate analysis. Conclusion: In patients with relapsed/ refractory T cell lymphomas, BV seems to have convincing antitumor activity with favorable safety profile.
dc.identifier.citationDARÇIN, T., SERIN, I., UGUR, M. C., EKINCI, O., YONAL-HINDILERDEN, I., AKPINAR, S., HACIBEKIROGLU, T., DEMIRCIOĞLU, S., GÜLTÜRK, E., ALBAYRAK, M., AYDOGDU, I., DAL, M. S., DOĞU, M. H., NAMDAROGLU, S., DOĞAN, A., NALCACI, M., TURGUT, B., BAŞCI, S., ALTUNTAS, F. (2024). Brentuximab Vedotin Monotherapy in Relapsed/Refractory T Cell Lymphoma Setting-Real Life Data. Hitit medical journal (Online) , 6(2), 186 - 192. doi.org/10.52827/hititmedj.1320606
dc.identifier.doi10.52827/hititmedj.1320606
dc.identifier.endpage192
dc.identifier.issue2
dc.identifier.startpage186
dc.identifier.trdizinid1247726
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/1247726/brentuximab-vedotin-monotherapy-in-relapsedrefractory-t-cell-lymphoma-setting-real-life-data
dc.identifier.urihttps://doi.org/10.52827/hititmedj.1320606
dc.identifier.urihttps://hdl.handle.net/20.500.12713/6543
dc.identifier.volume6
dc.indekslendigikaynakTR-Dizin
dc.institutionauthorDoğu, Mehmet Hilmi
dc.institutionauthoridMehmet Hilmi Doğu / 0000-0001-7237-2637
dc.language.isoen
dc.publisherHitit Üniverstesi Tıp Fakültesi
dc.relation.ispartofHitit medical journal (Online)
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectbrentuximab vedotin
dc.subjectrelapse
dc.subjectT cell lymphoma
dc.titleBrentuximab Vedotin Monotherapy in Relapsed/Refractory T Cell Lymphoma Setting-Real Life Data
dc.title.alternativeRelaps / Refrakter T Hücreli Lenfomada Brentuximab Vedotin Monoterapisi- Gerçek Yaşam Verisi
dc.typeArticle

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.17 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Dahili Tıp Bilimleri Bölümü Makale Koleksiyonu